Oncology

Human antibodies
#Antibodies #Epsilogen #Mergers and acquisitions #Oncology #Therapeutic Antibodies

Acquisition creates leading pan-isotype cancer antibody company

Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies.  As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors. … Read More

#Business & Investment #News

#Cancer Research Manchester Institute #Cell Science #Lung cancer #Non-animal model (NAM) #Oncology

Cell-based lung cancer model could unlock targeted treatments

Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease.   In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell… Read More

#Cancer Research #News

Trophy
#AACR #Award #Events #Janssen #Oncology

Janssen’s Hait honoured for achievements in cancer research

The 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research will be presented to William Hait, Fellow of the AACR Academy, during the AACR Annual Meeting 2025.  Hait served as the Global Head of Janssen Research and Development and was the executive vice president,… Read More

#Cancer Research #News

Meet The Exhibitor
#AI / data analytics / healthtech / informatics #Antibodies #Cancer research #Career #From the top #Genetics / genomics #Interview #Meet the Researcher #Oncology #Research and development #Sitting Down With #Women in STEM

New podcast: Getting to know key drug discovery leaders

This is the latest episode of the free DDW narrated podcast, titled “Getting to know key drug discovery leaders”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura”… Read More

#News

Colorectal cancer
#Artificial intelligence (AI) #Cancer Research Horizons #Colorectal cancer #Multi-omics #Oncology

Partners develop AI tools to personalise colon cancer treatment

Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.  As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from… Read More

#Business & Investment #Cancer Research #News

European Commission
#European Commission #Johnson & Johnson #Monoclonal antibodies #Oncology

EC approves subcutaneous use of J&J antibodies for cancer

The European Commission (EC) has approved an indication extension for two of Johnson & Johnson’s monoclonal antibody therapies in oncology.  The approval of Darzalex (daratumumab) has been extended to include a subcutaneous (SC) formulation in the frontline setting in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for… Read More

#News #Regulatory

Blushwood tree
#Head and neck cancer #Oncology #Plant-based #QBiotics #Solid tumours #The Institute of Cancer Research

Could a molecule from a rainforest tree treat solid tumour cancers?

Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.  The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More

#Cancer Research #Editor's Choice #News

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy… Read More

#News #Regulatory

X-ray showing colon cancer
#Bowel cancer #Cancer Research UK #Colorectal cancer #Oncology #Personalised medicine

CRUK commits £5.5m to transform bowel cancer treatment

Cancer Research UK and partners have committed £5.5 ($7.1) million in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer.  The CRC-STARS initiative will bring together over 40 research experts from across the UK, Spain, Italy and… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Genmab #Japan #Oncology

First ADC approved for cervical cancer in Japan

The Japan Ministry of Health, Labour and Welfare has approved Genmab’s Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after chemotherapy treatment.   Tivdak is the first antibody-drug conjugate (ADC) to be approved for people living with cervical cancer… Read More

#News #Regulatory

Lung cancer
#Clinical trial #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Rybrevant and Lazcluze extend survival in NSCLC

Results from its first-line MARIPOSA trial show that Rybrevant (amivantamab) plus Lazcluze (lazertinib) significantly extended overall survival (OS) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  The patients have NSCLC with epidermal growth factor receptor (EGFR)… Read More

#News

Institute of Cancer Research
#ATR inhibitors #Genetics / genomics #Oncology #The Institute of Cancer Research

Genetic study predicts success of ATR inhibitors in rare cancer

Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.  In clinical trials, ATR inhibitors have demonstrated efficacy as a treatment for various types of cancer,… Read More

#Cancer Research #Editor's Choice #News

Leukaemia
#Acute Myeloid Leukaemia #FDA #Haematology #Oncology #Pleco Therapeutics

Positive FDA outcome for PTX-252 in acute myeloid leukaemia

Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA).   The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat… Read More

#News #Regulatory

#Adverse event #Cancer research #CAR-T #Cardio #CRISPR #CRISPR-Cas9 #Drug discovery #Gene editing #Imaging #Oncology #Screening

New podcast: Innovation enabled by new drug discovery technologies

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of… Read More

#News